Standout Papers

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy a... 2019 2026 2021 2023 1.1k
  1. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial (2019)
    Howard West, Michael McCleod et al. The Lancet Oncology

Immediate Impact

4 by Nobel laureates 60 standout
Sub-graph 1 of 21

Citing Papers

Resistance mechanisms to immune checkpoint inhibitors: updated insights
2025 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
1 intermediate paper

Works of Wei Lin being referenced

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
Wei Lin 620 656 657 1096 838 148 3.0k
Sang-Ho Cho 521 263 214 263 458 135 2.3k
Yanyu Zhang 566 828 381 384 242 134 3.2k
Hajime Yamaguchi 893 258 458 132 482 172 3.5k
Tengfei Zhang 129 351 619 167 1252 249 4.2k
Tatsuo Tanaka 118 92 403 462 257 236 3.9k
Wei Li 763 260 1102 283 270 346 5.0k
Marko Hočevar 308 78 395 424 285 177 3.0k
Jianmin Yang 196 1113 255 191 393 269 4.8k
Yifan Zhang 249 379 74 328 183 126 2.0k
Toshiaki Setoguchi 319 1790 574 398 120 417 5.1k

All Works

Loading papers...

Rankless by CCL
2026